Table 1.
Characteristics of 2818 patients with COVID-19 who received monoclonal antibody therapy in ambulatory or emergency department setting.
| Variables | Overall (N=2818) | No inpatient visit (n=2673) | Inpatient visit (n=145) | P value | |||||
| Age (years), median (IQR) | 67.00 (58.00-74.00) | 66.00 (58.00-74.00) | 75.00 (64.00-82.00) | <.001 | |||||
| Age categories (years), n (%) | <.001 | ||||||||
|
|
<55 | 460 (16.3) | 450 (16.8) | 10 (6.9) |
|
||||
|
|
55-64 | 710 (25.2) | 683 (25.6) | 27 (18.6) |
|
||||
|
|
65-74 | 964 (34.2) | 930 (34.8) | 34 (23.4) |
|
||||
|
|
≥75 | 684 (24.3) | 610 (22.8) | 74 (51.0) |
|
||||
| Female sex, n (%) | 1406 (49.9) | 1343 (50.2) | 63 (43.4) | .13 | |||||
| Race/ethnicity, n (%) | .39 | ||||||||
|
|
Hispanic | 168 (6.0) | 160 (6.0) | 8 (5.5) |
|
||||
|
|
Non-Hispanic Black | 104 (3.7) | 99 (3.7) | 5 (3.4) |
|
||||
|
|
Asian | 110 (3.9) | 103 (3.9) | 7 (4.8) |
|
||||
|
|
Non-Hispanic White | 2061 (73.1) | 1948 (72.9) | 113 (77.9) |
|
||||
|
|
Other/multiracial | 332 (11.8) | 323 (12.1) | 9 (6.2) |
|
||||
|
|
Unknown/declined | 43 (1.5) | 40 (1.5) | 3 (2.1) |
|
||||
| Comorbidities, n (%) | |||||||||
|
|
Obesity | 401 (23.3) | 377 (23.4) | 24 (21.4) | .71 | ||||
|
|
Diabetes mellitus | 484 (17.2) | 421 (15.8) | 63 (43.4) | <.001 | ||||
|
|
Hypertension | 1011 (35.9) | 901 (33.7) | 110 (75.9) | <.001 | ||||
|
|
Chronic kidney disease | 113 (4.0) | 85 (3.2) | 28 (19.3) | <.001 | ||||
|
|
Chronic obstructive pulmonary disease | 434 (15.4) | 394 (14.7) | 40 (27.6) | <.001 | ||||
|
|
Chronic respiratory disease | 463 (16.4) | 418 (15.6) | 45 (31.0) | <.001 | ||||
|
|
Immunosuppressed | 179 (6.4) | 161 (6.0) | 18 (12.4) | .004 | ||||
| COVID-19 symptoms, n (%) | |||||||||
|
|
Cough | 1954 (70.4) | 1847 (70.2) | 107 (74.3) | .34 | ||||
|
|
Malaise | 1471 (53.0) | 1398 (53.1) | 73 (50.7) | .63 | ||||
|
|
Fever | 1422 (51.2) | 1350 (51.3) | 72 (50.0) | .83 | ||||
|
|
Headache | 820 (29.5) | 788 (30.0) | 32 (22.2) | .06 | ||||
|
|
Sore throat | 555 (20.0) | 532 (20.2) | 23 (16.0) | .26 | ||||
|
|
Gastrointestinal | 371 (13.4) | 351 (13.3) | 20 (13.9) | .95 | ||||
|
|
Loss taste/smell | 309 (11.1) | 296 (11.3) | 13 (9.0) | .49 | ||||
|
|
Muscle pain | 256 (9.2) | 240 (9.1) | 16 (11.1) | .51 | ||||
|
|
Shortness of breath | 143 (5.2) | 131 (5.0) | 12 (8.3) | .11 | ||||
| Monoclonal antibody type, n (%) | .30 | ||||||||
|
|
Casirivimab/imdevimab | 317 (11.2) | 305 (11.4) | 12 (8.3) |
|
||||
|
|
Bamlanivimab | 2501 (88.8) | 2368 (88.6) | 133 (91.7) |
|
||||
| Monoclonal antibody timing, median (IQR) | |||||||||
|
|
Days from symptom onset to therapy | 6.00 (4.00-8.00) | 6.00 (4.00-8.00) | 6.00 (5.00-8.00) | .39 | ||||
|
|
Days from symptom onset to COVID-19 test | 2.00 (1.00-3.00) | 2.00 (1.00-3.00) | 2.00 (1.00-3.25) | .03 | ||||
| EDa and hospital use | |||||||||
|
|
ED visit within 28 days, n (%) | 123 (4.4) | 112 (4.2) | 11 (7.6) | .08 | ||||
|
|
Days from COVID-19 test to ED visit, median (IQR) | 7.00 (5.00-11.00) | 7.00 (5.00-11.00) | 6.00 (3.00-10.50) | .49 | ||||
|
|
Days from therapy to ED visit, median (IQR) | 3.00 (0.00-6.00) | 3.00 (0.00-6.00) | 2.00 (0.50-4.50) | .56 | ||||
|
|
Days from COVID-19 test to hospitalization, median (IQR) | N/Ab | N/A | 7.00 (5.00-11.00) | N/A | ||||
|
|
Days from therapy to hospitalization, median (IQR) | N/A | N/A | 3.00 (1.00-8.00) | N/A | ||||
aED: emergency department.
bN/A: not applicable.